23 Feb 2016
Palbociclib (Ibrance, Pfizer), a cyclin-dependent kinase 4/6 inhibitor, is approved for use in combination with fulvestrant for the treatment of women with hormone receptor-positive, HER-2–negative metastatic breast cancer who progressed on endocrine therapy.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024